- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
How Virtual Support Can Help Family Caregivers
Eric Rackow, MD, cofounder and executive chairman of eFamilyCare, discusses the importance of virtual support for family caregivers.
Eric Rackow, MD, cofounder and executive chairman of eFamilyCare, discusses the importance of virtual support for family caregivers.
Transcript
Why is it so important to have virtual support for family caregivers, and how does it compare to other forms of support?
Well, there are many forms of support for family caregivers. Support can be in person in the house, or it can be a training episode or program with health care workers, or it could be Googling the Internet for information—but caregivers find that pretty overwhelming. We find that with virtual support, we can continuously help the caregiver understand the tasks they face, advise them on how to accomplish those tasks, and help reduce their stress. So, the virtual technology, in this case a proprietary app that we have, allows family caregivers to have ongoing support when they need it and when they ask to receive it. It's a good way to communicate with family caregivers.
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
April 23rd 2025For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
